RecruitingPhase 2NCT06527222

A Study of Ranolazine in ALS

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Swathy Chandrashekhar, MBBS
Principal Investigator
Jeffrey Statland, MD
University of Kansas Medical Center
Intervention
Ranolazine(drug)
Enrollment
72 enrolled
Eligibility
18 years · All sexes
Timeline
20252026

Study locations (7)

Collaborators

ALS Association

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06527222 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials